Last reviewed · How we verify
Pharmacological ascorbate
At a glance
| Generic name | Pharmacological ascorbate |
|---|---|
| Also known as | Ascorbate, Vitamin C, Ascorbic acid, ASCOR, vitamin C |
| Sponsor | Joseph J. Cullen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
- Ascorbate in Myelodysplastic Syndrome (PHASE2)
- Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE1)
- The Effect of Nutritional Supplementation on Actinic Purpura: A Pilot Study (NA)
- High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) (PHASE1)
- The Effect of Vitamin C Supplementation on Gut Microbiota Composition and Function in Healthy Adults (NA)
- Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer (PHASE2)
- Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pharmacological ascorbate CI brief — competitive landscape report
- Pharmacological ascorbate updates RSS · CI watch RSS
- Joseph J. Cullen portfolio CI